Assessment of the Efficacy of Immunomodulatory Therapy With Thymosin Alpha 1 (Tα1) Following Surgical Resection in Patients With Stage I Non-Small Cell Lung Cancer
To explore the effect of thymosin alpha 1 (Tα1) on postoperative peripheral blood circulating tumor cells and immunosenescence in patients with early-stage non-small cell lung cancer (NSCLC).
• Pathologically confirmed stage I (per AJCC 8th edition) invasive NSCLC
• Resectable tumor
• undergoing lobectomy and systemic lymph node dessection
• Without a previous history of malignant tumors or other concurrent malignancies
• Naïve to any anticancer therapies or other immunostimulatory agents
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0-1, with cardiac, pulmonary, hepatic, cerebral, and renal functions capable of withstanding surgery
• Aged ≥18 years and ≤75 years
• Having signed written informed consent and capable of adhering to the visit schedule and related procedures outlined in the study protocol